Cagrilintide

Cagrilintide from Super Human Peptides UK is a highly advanced, synthetic, long-acting peptide analogue of the naturally occurring pancreatic hormone amylin (islet amyloid polypeptide). In laboratory research, Cagrilintide represents a massive paradigm shift in metabolic modeling. While standard anti-obesity peptides rely on the GLP-1 or GIP incretin pathways, researchers utilize Cagrilintide as a potent, non-selective agonist of both the amylin (AMYR) and calcitonin (CTR) receptors.

Because it operates on this entirely separate pathway, it physically delays gastric emptying and directly stimulates the satiety centers located in the hindbrain (the area postrema), forcefully signaling the brain that the body is full. Produced under GMP-compliant conditions and verified for 99% purity or higher, Cagrilintide is an unparalleled tool for investigating severe obesity, synergistic weight loss models (often paired with GLP-1 agonists), and advanced glucagon suppression.

• —Long-Acting Amylin Analogue: Mimics the endogenous hormone co-secreted with insulin to regulate post-meal blood sugar and digestion rates.
• —Dual Receptor Agonist: Binds powerfully to both amylin and calcitonin receptors to trigger profound satiety cascades.
• —Non-Incretin Pathway: Operates independently of the GLP-1 receptor, making it a critical model for synergistic (combination) therapies.
• —Gastric Emptying Delay: Physically slows the transit of food from the stomach to the intestines, prolonging physical fullness.
• —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
• —Quality Standard: GMP / ISO certified manufacturing.

• —Hindbrain Receptor Activation: Studying the peptide's ability to cross the blood-brain barrier and specifically target the area postrema to regulate feeding behavior and induce meal termination.
• —Synergistic Weight Loss Models: Preclinical modeling of co-administering Cagrilintide with GLP-1 agonists (such as Semaglutide) to observe compounding, exponential reductions in body mass index.
• —Gastric Motility: Measuring the pharmacological delay in the rate at which the stomach empties its contents into the duodenum.
• —Glucagon Suppression: Investigating the dose-dependent blunting of postprandial (post-meal) glucagon secretion, which drastically lowers circulating blood glucose levels.
• —Pancreatic Stress Reduction: Evaluating the compound's ability to lower the body's overall demand for insulin, thereby protecting beta cells from exhaustion in diabetic models.

Cagrilintide was developed by Novo Nordisk as the ultimate companion peptide to their flagship GLP-1 agonists. Researchers hypothesized that by attacking obesity from two completely different neurological and physical pathways (incretin and amylin), they could shatter the weight-loss ceiling established by earlier mono-agonists. Laboratory and advanced clinical modeling of Cagrilintide has yielded spectacular metabolic results.

In foundational studies, subjects administered Cagrilintide alone demonstrated severe appetite suppression and substantial, sustained weight loss. However, when researchers combined Cagrilintide with Semaglutide (a combination known in trials as CagriSema), the results were unprecedented. Animal models and human trial data routinely show body mass reductions exceeding 20% to 25%, heavily outperforming either peptide used in isolation.

Because it reliably compounds the effects of existing metabolic treatments without competing for the same receptors, it is currently one of the most highly prioritized compounds in modern endocrinology.

• 1.Enebo, A.M. et al., "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial," The Lancet, 2021.
• 2.Kruse, T. et al., "Cagrilintide, a long-acting amylin analogue, for weight management," Obesity, 2021.
• 3.Deeks, E.D. et al., "Cagrilintide: First Approval," Drugs, 2022. (Contextual data on AMYR agonism).
• 4.Lau, J. et al., "Discovery of the Once-Weekly Amylin Analogue Cagrilintide," Journal of Medicinal Chemistry, 2021.